Trials / Terminated
TerminatedNCT02991131
Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study
DART: "Sivextro® in Acute Bacterial Skin anD Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global ObseRvational STudy."
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 108 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label, prospective, multi-center, non-interventional, observational, parallel cohort study intended to provide real life data on the treatment duration, effectiveness and safety of tedizolid and linezolid when treating ABSSSI hospitalized patients in a real practice setting.
Detailed description
The primary objective of this study was to assess the treatment duration in the real life in 2 cohorts consisting of patients treated by 200 mg once daily IV/PO tedizolid or treated by 600 mg twice daily IV/PO (intravenous/per oral) linezolid.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tedizolid (Sivextro, BAY1192631) | Antibiotic |
| DRUG | Linezolid | Antibiotic |
Timeline
- Start date
- 2016-12-17
- Primary completion
- 2018-11-21
- Completion
- 2018-11-21
- First posted
- 2016-12-13
- Last updated
- 2019-10-02
Locations
3 sites across 3 countries: Mexico, Russia, Singapore
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02991131. Inclusion in this directory is not an endorsement.